PATENT CLAIM ANALYSIS

Application Number: 15979041
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "402000"]

Abstract:
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

Claim (Index 3):
The method of  claim 1  wherein the drug therapy comprises administration of a derivative or analog of bisantrene selected from the group consisting of:\n (a) the analog of Formula (II) \n (b) the bisantrene analog of Formula (III) (c) the bisantrene analog of Formula (IV) (d) the bisantrene analog of Formula (V) (e) the bisantrene analog of Formula (VI) (f) the bisantrene analog of Formula (VII) (g) the bisantrene analog of Formula (VIII) (h) the bisantrene analog anthracen-9-ylmethylene-[2-methoxyethoxymethylsulfanyl]-5-pyridin-3-yl-[1,2,4]triazol-4-amine; (i) the bisantrene analog of Formula (X) (j) the bisantrene analog of Formula (XI) (k) the bisantrene analog of Formula (XII) (l) the bisantrene analog of Formula (XIII) (m) bisantrene analogs of Formula (XIV) wherein R 1  and R 3  are the same or different and are hydrogen, C 1 -C 6  alkyl, \u2014C(O)\u2014R 5 , wherein R 5  is hydrogen, C 1 -C 6  alkyl, phenyl, mono-substituted phenyl (wherein the substituent can be ortho, meta, or para and is fluoro, nitro, C 1 -C 6  alkyl, C1-C 3  alkoxy, or cyano), pentafluorophenyl, naphthyl, furanyl, or \u2014SO 3 H; wherein only one of R 1  and R 3  may be hydrogen or C 1 -C 6  alkyl; R 2  and R 4  are the same or different and are: hydrogen, C 1 -C 4  alkyl or \u2014C(O)\u2014R 6 , where R 6  is hydrogen, C 1 -C 6  alkyl, phenyl, mono-substituted phenyl (wherein the substituent may be in the ortho, meta, or para position and is fluoro, nitro, C 1 -C 6  alkyl, C 1 -C 3  alkoxy, or cyano), pentafluorophenyl, naphthyl, furanyl, or \u2014CH 2 OCH 3 . The compounds can have the schematic structure B(Q) n , wherein B is the residue formed by removal of a hydrogen atom from one or more basic nitrogen atoms of an amine, amidine, guanidine, isourea, isothiourea, or biguanide-containing pharmaceutically active compound, and Q is hydrogen or A, wherein A is such that R\u2032 and R\u2033 are the same or different and are R (where R is C 1 -C 6  alkyl, aryl, aralkyl, heteroalkyl, NC\u2014CH 2 CH 2 \u2014, Cl 3 C\u2014CH 2 \u2014, or R 7 OCH 2 CH 2 \u2014, where R 7  is hydrogen or C 1 -C 6  alkyl, hydrogen, or a pharmaceutically acceptable cation or R\u2032 and R\u2033 are linked to form a \u2014CH 2 CH 2 \u2014 group or a group, and n is an integer representing the number of primary or secondary basic nitrogen atoms in the compound such that at least one Q is A;\n (n) the bisantrene analog 9,10-bis[(2-hydroxyethyl)iminomethyl]anthracene; \n (o) the bisantrene analog 9,10-bis{[2-(-2-hydroxyethylamino)ethyl]iminomethyl}anthracene; \n (p) the bisantrene analog 9,10-bis{[2-(-2-hydroxyethylamino)ethyl]iminomethyl}anthracene; \n (q) the bisantrene analog 9,10-bis{[2-(morpholin-4-yl)ethyl]iminomethyl}anthracene; \n (r) the bisantrene analog 9,10-bis[(2-hydroxyethyl)aminomethyl]anthracene; \n (s) the bisantrene analog 9,10-bis{[2-(2-hydroxyethylamino)ethyl]aminomethyl}anthracene tetrahydrochloride; \n (t) the bisantrene analog 9,10-bis{[2-(piperazin-1-yl)ethyl]aminomethyl}anthracene hexahydrochloride; \n (u) the bisantrene analog 9,10-bis{[2-(morpholin-4-yl)ethyl]aminomethyl}anthracene tetrahydrochloride; \n (v) N, N\u2032-bis[2-(dimethylamino)ethyl]-9,10-anthracene-bis(methylamine); \n (w) N, N\u2032-bis(1-ethyl-3-piperidinyl)-9,10-anthracene-bis(methylamine); and \n (x) salt forms of the compounds of (a)-(w).

Metadata:
- Claim Count in Document: 17.0
- Percentile: 93.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14907728', '14907729', '13817096', '14753911', '14245738']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7896975434409267
- 35 USC 102 Novelty (BERT): 0.53505517656745
- Combined Prediction Score: 0.764233306753579
- Mean Citation Score: 267.787678
- Max Citation Score: 348.62634
- Similarity Product: 225.05276667155383

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test